<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097252</url>
  </required_header>
  <id_info>
    <org_study_id>KCCH GY 1005</org_study_id>
    <nct_id>NCT01097252</nct_id>
  </id_info>
  <brief_title>Weekly Versus Three-week Chemoradiation in Patients With Advanced Cervical Cancer</brief_title>
  <official_title>Randomized Trial of Concurrent Chemoradiation With Weekly Versus Three-week Cisplatin in Patients With Advanced Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Cancer Center Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Cancer Center Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Three weekly cisplatin based chemoradiation is to be compared the compliance, toxicity, and
      response rates with the weekly cisplatin based chemoradiation in the treatment of
      locoregionally advanced cervical cancers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is to compare the compliance, toxicity, response and survival rate between
      concurrent chemoradiation with weekly cisplatin 40mg/m2 and three-week cisplatin 75mg/m2 in
      patients with advanced cervical cancer. Patients with primary untreated invasive squamous
      cell carcinoma, adenosquamous carcinoma or adenocarcinoma of the cervix from stage IIB to IVA
      were enrolled. Patients with histologically proven locoregionally advanced cervical cancer
      will be randomized into two treatment arm; Arm I, concurrent chemoradiation with weekly
      cisplatin 40mg/m2 for six times; Arm II, concurrent chemoradiation with three-week cisplatin
      75mg/m2 for three times. The compliance and toxicity during the chemoradiation is the primary
      endpoint. Response rate and the overall survival will be analyzed as secondary endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>compliance</measure>
    <time_frame>3 month</time_frame>
    <description>Percentage of completed cycles of scheduled chemotherapy in each arm
Percentage of grade III and IV toxicity
Delayed radiation time due to toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>5 years</time_frame>
    <description>5 year progression free survival
5 year survival rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Cervical Cancers</condition>
  <arm_group>
    <arm_group_label>weekly cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Weekly cisplatin 40mg/m2 during radiation therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tri-weekly cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cisplatin 75mg/m2 three cycles, every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation</intervention_name>
    <description>radiation with cisplatin 40mg/m2, 6 cycles, every week</description>
    <arm_group_label>weekly cisplatin</arm_group_label>
    <arm_group_label>tri-weekly cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>weekly cisplatin</intervention_name>
    <description>weekly cisplatin 40mg/m2, 6 cycles</description>
    <arm_group_label>weekly cisplatin</arm_group_label>
    <other_name>Cisplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tri-weekly cisplatin</intervention_name>
    <description>cisplatin 75mg/m2, 3cycles, every 3 weeks</description>
    <arm_group_label>tri-weekly cisplatin</arm_group_label>
    <other_name>Cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven cervical cancer

          -  Squamous, Adenosquamous, Adeno carcinoma cell type

          -  International Federation of Gynecologic Oncology (FIGO) stage IIB - IVA

          -  Gynecologic Oncology Group (GOG) performance status 0 - 2

        Exclusion Criteria:

          -  Previous history of chemotherapy or radiation

          -  History of other cancer

          -  Hypersensitivity to platinum agents

          -  Pregnancy

          -  Serious medical disease
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-Young Ryu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea Institute of Radiological &amp; Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Korea Institute of Radiological &amp; Medical Sciences</name>
      <address>
        <city>Seoul</city>
        <zip>139-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Ryu SY, Lee WM, Kim K, Park SI, Kim BJ, Kim MH, Choi SC, Cho CK, Nam BH, Lee ED. Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e577-81. doi: 10.1016/j.ijrobp.2011.05.002. Epub 2011 Aug 11.</citation>
    <PMID>21840137</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2010</study_first_submitted>
  <study_first_submitted_qc>March 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2010</study_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea Cancer Center Hospital</investigator_affiliation>
    <investigator_full_name>Sang-Young Ryu</investigator_full_name>
    <investigator_title>Chair of Cerivcal/Ovarian Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Cervical Neoplasm</keyword>
  <keyword>chemoradiation</keyword>
  <keyword>compliance</keyword>
  <keyword>toxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

